Cargando…

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

Research in nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), has been limited by the availability of suitable models for this disease. A number of rodent models have been described in which the relevant liver pathology develops in an appropriate metabolic cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imajo, Kento, Yoneda, Masato, Kessoku, Takaomi, Ogawa, Yuji, Maeda, Shin, Sumida, Yoshio, Hyogo, Hideyuki, Eguchi, Yuichiro, Wada, Koichiro, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856038/ https://www.ncbi.nlm.nih.gov/pubmed/24192824 http://dx.doi.org/10.3390/ijms141121833

Ejemplares similares

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
por: Yoneda, Masato, et al.
Publicado: (2017)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2018)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
por: Honda, Yasushi, et al.
Publicado: (2017)

Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
por: Sumida, Yoshio, et al.
Publicado: (2012)

Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model
por: Kishida, Yumi, et al.
Publicado: (2017)

Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study
por: Kuwashiro, Takuya, et al.
Publicado: (2019)

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2010)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort
por: Imajo, Kento, et al.
Publicado: (2021)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial
por: Kamata, Yohei, et al.
Publicado: (2022)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic
por: Sumida, Yoshio, et al.
Publicado: (2021)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_62spdnfqsjgl39rtnafrss4f2s